CClinicalTrials.gg
CompletedNCT06319443Updated Aug 17, 2025

Daily Vinegar Ingestion and 24-Hour Blood Glucose Control

An interventional study of Liquid vinegar and vinegar pill in Glucose Intolerance, sponsored by Arizona State University. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-17.

Sponsored by Arizona State University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

When linking dietary interventions and blood glucose management, much of the existing research - particularly studies exploring the effects of vinegar - has relied on discrete readings from the conventional testing methods: blood samples or glucometers. These methods lack the capacity to provide insights into blood glucose dynamics 24/7.

Recognizing this gap, the current study aims to utilize continuous glucose monitoring to examine the impact of daily vinegar ingestion on glucose variability in adults identified as glucose intolerant.

Read the detailed description

Participants are randomly assigned to either Group A or Group B using the Microsoft Excel randomization function. Group A will be instructed to consume 4 tablespoons of red wine vinegar (2 tablespoons diluted in water at the start of the lunch and the dinner meals) for the first 4 days of the trial. Conversely, participants in Group B will ingest the placebo for the initial 4 days, ingesting one pill daily upon waking in the morning. On days 5-9, participants will switch to the opposite treatment. The red wine vinegar dosage (4 tablespoons containing 3.5 g acetic acid - this is the amount of acetic acid in a large 4-inch dill pickle), and the placebo vinegar pill dosage (one pill containing 0.022 g acetic acid) will be taken daily during the trial. On visit 1, anthropometric measurements, including height, weight, and body composition (lean fat mass and body fat mass), will be measured, and the continuous glucose monitor will be placed on the upper arm. The participants will be instructed to fast >8 hours (no food or beverages with the exception of water) ahead of visit 1. To ensure accurate use and data collection, researchers discussed the operation of CGM devices and that these waterproof devices are to be continuously worn during the entire 9-day trial and will be removed on day 9 (visit 2).

02

Conditions studied

  • Glucose Intolerance

Browse trials for

Keywords

  • glucose
  • continuous glucose monitoring
  • vinegar
03

In context

Glucose Intolerance

778 studies on the registry are indexed under Glucose Intolerance; 129 are open to participants now.

This study's enrollment of 10 is below the median of 60 across 645 interventional studies indexed under Glucose Intolerance.

Browse Glucose Intolerance studies →

Lead sponsor

Arizona State University is the lead sponsor of 234 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • glucose intolerance (defined as one of the following: fasting glucose >99 mg/dl; diagnosis of prediabetes or diabetes; history of gestational diabetes)
  • 18 years of age or older
  • sedentary or moderately active (defined as a score ≤ 24 on the Godin-Shepard Leisure Time Physical Activity Questionnaire)

Exclusion criteria

Exclusion Criteria:

  • currently adhering to a non-typical diet that would impact carbohydrate intake (including weight loss diets)
  • medication/drug use that has not been consistent for the previous 3 months or will be discontinued during the trial
  • any acute illness
  • regular smokers, pregnant or lactating women, or individuals taking insulin
  • Unwilling to tolerate vinegar ingestion
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Liquid vinegar

    Liquid vinegar (6% acidity) consumed at a dosage of 2 tablespoons (diluted in water and consumed at mealtime) twice daily (4 tablespoons total per day).

    Dietary Supplement: Liquid vinegar

  • Placebo comparator
    Vinegar pill

    One pill consumed daily in the morning.

    Dietary Supplement: vinegar pill

Interventions

  • Dietary supplementLiquid vinegar

    3.5 g acetic acid

  • Dietary supplementvinegar pill

    0.022 g acetic acid

06

What researchers measure

Primary outcomes

  1. Average glucose

    The average blood glucose concentration for each 4-day period

    Time frame: Four days

  2. Glucose: time in range

    The average time over 4 days that blood glucose falls in the reference range

    Time frame: Four days

07

Study locations

1 site
  • 850 PBC
    Phoenix, Arizona 85004, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06319443
Lead sponsor
Arizona State University
Responsible party
Carol Johnston (Professor and Associate Dean, Arizona State University) — Principal investigator
First posted
Mar 20, 2024
Start date
Mar 26, 2024
Primary completion
Dec 15, 2024
Completion
Jul 15, 2025
Last update
Aug 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion